News

PRESS RELEASE One trial seeks to reduce wandering in dementia patients; the other targets two rare, deadly neurodegenerative diseases. NEW YORK, February 18, 2021 — Woolsey Pharmaceuticals, a clinical-stage company developing treatments for neurodegenerative diseases, today announced dosing of the first patient with BRAVYL in its FOUND (Fasudil fOr Uncontrolled waNDering) study for Alzheimer’s and […]

NEW YORK, NY – March 11, 2020 – Woolsey Pharmaceuticals announced today that it completed a round of financing that will fund operations through the completion of a planned clinical study. The amount was not disclosed but the financing was substantially oversubscribed, according to company officials. The Company also announced the appointment of two outside

NEW YORK, NY – December 2, 2019 –Embark Healthcare announced today the launch of two new repurposed drug companies, Woolsey Pharmaceuticals and Learmont Pharmaceuticals.  EMBARK HEALTHCARE is made up of a diverse group of companies within the pharmaceutical industry. While each is unique in the field of medicine it is pursuing, all are “Indication Discovery Companies,”

NEW YORK, NY – December 2, 2019 – After almost two decades since its inception, Carrot Capital Healthcare Partners announces a corporate name change to Embark Healthcare.  The new name better reflects our role as an “Indications Discovery Company.” Embark Healthcare doesn’t discover new drugs. Instead, we discover new ways to use existing drugs for other

NEW YORK, NY – November 25, 2019 – Woolsey Pharmaceuticals announced today that it completed a license agreement with Japanese pharmaceutical company Asahi Kasei Pharma Corporation, for rights to its drug, fasudil. The agreement grants Woolsey Pharmaceuticals the rights to develop and manufacture, and exclusive rights to commercialize any formulations (other than ophthalmic and injectable forms)

NEW YORK, NY – October 22, 2019 – Embark Healthcare announced today that Biogen (Nasdaq:BIIB), an American multinational biotechnology company based in Cambridge, Massachusetts and specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide, reported that it enrolled the first patient in a phase 2 brain contusion